LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia's forecast of more than $1 billion in 2027 net revenue.

Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares dropped 6.1% on Monday after Wells Fargo and Company downgraded the stock from an overweight rating to an equal weight rating. Wells Fargo and Company now has a $30.00 price target on the stock. Liquidia traded as low as $25.92 and last traded at $26.8880. 1,088,644 shares

LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) are rising in Thursday morning trading following a federal court victory in its patent litigation against competitor Liquidia Corp.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics' patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).“We are pleased with the Co.

Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by ​rival United Therapeutics , dealing a major blow to the treatment's ‌commercial outlook.

YUTREPIA's adoption is translating into profits and cash, giving Liquidia an operating foundation for further growth. LQDA is already generating substantial cash flows, even though YUTREPIA's growth phase remains in its early stages. The main risk I believe is worth monitoring is LQDA's ongoing legal battle with UTHR over potential patent infringement.

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.